News | May 08, 2026
Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The product is approved as bioequivalent to Xigduo XR for the indications outlined in the reference drug’s labelling
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The initiative is aimed at strengthening the district-level screening and chronic disease management infrastructure
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Subscribe To Our Newsletter & Stay Updated
